+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Product and Pipeline Analysis of the Global Colorectal Cancer Market

  • ID: 3394142
  • Report
  • September 2015
  • Region: Global
  • 105 Pages
  • Frost & Sullivan
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
Targeted Therapeutics and Immunology Combine to Take Colorectal Cancer Treatments to the Next Level


  • Bayer
  • BMS
  • Boston Biomedical
  • Genentech
  • Mologen
  • Roche
  • MORE
This research service on the global colorectal cancer market provides in-depth analyses of industry trends, market shares, competitive analysis, market opportunities and revenue forecasts from 2014 to 2021. It also features a SWOT analysis of drugs that are available in the market as well as those under development. In this market research expert analysts thoroughly examine the following modalities:

- Targeted therapies
- Cytotoxics
- Cancer vaccines
- Other products (bone calcium regulators, cytotoxic antibiotics, anti-cancer agents, immunostimulants, alkylating agents and anti-metabolites).

The evaluation of each drug class is supported by information on clinical trials, projected launch timelines, and epidemiology.
Note: Product cover images may vary from those shown
2 of 4


  • Bayer
  • BMS
  • Boston Biomedical
  • Genentech
  • Mologen
  • Roche
  • MORE
1. Executive Summary
  • Physician Treatment Guidelines-Lines of Therapy
  • Key Trends
  • Market Opportunities
  • Companies to Watch
2. Methodology and Scope

3. Market Overview
  • Market Overview-Types of Treatment in Development
  • Market Overview-Global Incidences of CRC
  • Market Overview-US Incidence Rates by Year and Sex
  • Market Overview-Biomarker Type Segmentation
  • Market Overview-Key Mergers, Acquisitions, and Partnerships
  • Market Overview-Recent Developments
4. Revenue Forecast
  • Global CRC Market-Revenue Forecast
  • Revenue Forecast Discussion
5. Competitive Landscape
  • Competitive Landscape Overview
  • Competitive Landscape-Phase III to Launch
  • Competitive Landscape-Phase II
  • Competitive Landscape-Phase I
6. Marketed Products
  • Key Marketed Products
7. Pipeline Drugs Analysis
  • Pipeline Synopsis-Phase III
  • Pipeline Synopsis-Phase II
  • Pipeline Synopsis-Phase I
  • Competitive Landscape-Pivotal Phase III Trials
  • Timeline of Key Events
  • Patent Expirations
  • Pipeline Discussion
8. Product Dashboard of Recently Approved Drugs and Late-stage Pipeline Drug Candidates
  • Product Dashboard: Avastin (Bevacizumab)-Genentech Inc. (Roche Group)
  • Avastin (Genentech, Roche)-SWOT Analysis
  • Product Dashboard-BBI503: Boston Biomedical
  • BBI503 (Boston Biomedical)-SWOT Analysis
  • Product Dashboard-Cyramza (ramicirumab): Eli Lilly
  • Cyramza (ramicirumab) (Eli Lilly)-SWOT Analysis
  • Product Dashboard-Erbitux (cetuximab): Eli Lilly/BMS/Merck
  • Erbitux (Eli Lilly, BMS, and Merck)-SWOT Analysis
  • Product Dashboard-Imprime PGG: Biothera
  • Imprime PGG (Biothera)-SWOT Analysis
  • Product Dashboard-Lonsurf (TAS-102): Taiho (Otsuka)
  • Lonsurf (TAS-102) (Taiho, Otsuka)-SWOT Analysis
  • Product Dashboard-MGN1703: Mologen
  • MGN1703 (Mologen)-SWOT Analysis
  • Product Dashboard-Nintedanib (BIBF-1120, OFEV): Boehringer Ingelheim
  • Nintedanib (BIBF-1120, OFEV) (BI)-SWOT Analysis
  • Product Dashboard-Stivarga (regorafenib): Bayer/Onyx Pharmaceuticals
  • Stivarga (Bayer, Onyx)-SWOT Analysis
  • Product Dashboard-Zaltrap (aflibercept): Sanofi
  • Zaltrap (aflibercept) (Sanofi)-SWOT Analysis
9. Conclusions
  • The Last Word-3 Big Predictions
  • The Last Word-Discussion
  • Legal Disclaimer
10. The Publisher's Story
  • Value Proposition: Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360º Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Note: Product cover images may vary from those shown
3 of 4


  • Bayer
  • BMS
  • Boston Biomedical
  • Genentech
  • Mologen
  • Roche
  • MORE
Strong drug pipeline continues to expand:

The pipeline for colorectal cancer treatment boasts a vast number and variety of remedies. The high incidence of the disease, unmet treatment needs and their commercial potential attracts drug developers to the market. Advancements are centred on identifying new molecular targets and reducing toxicity. Several immunotherapies and cancer vaccines are being developed as pharmaceutical and biotech companies attempt to utilise the body's own immune system mechanism to attack tumours. Immune-based therapies will play a vital role in future cancer treatment as they can increase survival rates and overcome patients' resistance to existing therapeutics.

Colorectal cancer care edges toward personalisation:

With the increasing focus on treatment outcomes, the market for colorectal cancer is undoubtedly moving toward personalised modes of care. Targeted solutions dominate the colorectal cancer pipeline, accounting for 60 percent of the treatment modalities under production. The improved understanding of the molecular mechanisms of colorectal cancer will facilitate the identification of newer targets and give rise to multi-targeted therapies. Meanwhile, biomarker testing is expected to become the standard of care, as it can help select a targeted therapy for a patient's particular need (predictive biomarkers), as well as define the patient's specific tumour type (prognostic biomarkers).

Beyond effective care delivery, employing targeted solutions will greatly enhance the reimbursement potential. By treating patients that are most likely to respond to a particular therapy, healthcare givers will be able to better justify the high costs to insurance firms and government payers. Therefore, clinical trials of targeted therapy drugs using biomarkers as surrogate endpoints will boost their chances of approval. Ultimately, the use of targeted remedies, coupled with immunotherapy, though complicated, will bridge the gap between the current need and future scope of colorectal cancer treatment globally.
Note: Product cover images may vary from those shown
4 of 4
- Bayer
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Eli Lilly
- Genentech
- Merck
- Mologen
- Onyx Pharmaceuticals
- Roche
- Sanofi
- Taiho (Otsuka)

Note: Product cover images may vary from those shown